It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Links Up with Chinese Biopharma to Streamline Search for Seed Compounds
December 12, 2018
- DS-8201 Yields 44.2% ORR in HER2-Low Breast Cancer: Daiichi Sankyo
December 11, 2018
- Avastin Top-Seller Drug in Japan for 4 Months Running: Encise Snapshot
December 11, 2018
- Pfizer Marks Foray into Japan Biosimilar Market with Remicade Follow-On
December 11, 2018
- Mitsubishi Tanabe Begins Study to Identify ALS Biomarkers
December 11, 2018
- Shionogi, Ube Join Hands on Respiratory Syncytial Virus Research
December 11, 2018
- Daiichi Sankyo Grabs Top Spot in Combined Approach of Sales Reps’ Visits, e-Detailing: Survey
December 11, 2018
- Roche Diagnostics Files PD-L1 Test Kit for Imfinzi in Japan
December 10, 2018
- Tecentriq Filed in Japan for 1st Line SCLC: Chugai
December 10, 2018
- RaQualia Launches New Subsidiary for Commercialization of New Projects
December 10, 2018
- Pfizer Files Rheumatrex for Psoriasis Based on Information in Public Domain
December 10, 2018
- Chugai’s Tecentriq Gets Orphan Status in SCLC, Entrectinib in NTRK-Mutated Solid Tumors
December 7, 2018
- Shionogi Set to Get Its Hands on Vast’s Nitric Oxide-Releasing Antimicrobial Agent
December 7, 2018
- Eisai/UCL’s Anti-Tau Antibody Heading into PI for Alzheimer’s Disease
December 7, 2018
- U3-1402 Racks Up 42.9% Response Rate in Breast Cancer Study: Daiichi Sankyo
December 7, 2018
- Teva Takeda Yakuhin Applies for Pediatric Use for Blopress Based on Information in Public Domain
December 7, 2018
- Fuji Yakuhin, Pfizer to Terminate Copromotion for Topiloric in January
December 7, 2018
- Pfizer to Transfer Antiepileptic Agent Gabapen to Fuji Pharma
December 7, 2018
- Chugai Sues Alexion Japan over Soliris Successor ALXN1210 after US
December 6, 2018
- Amicus Aims to Expand Rare and Intractable Disease Pipeline in Japan
December 6, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…